Kaiser Washington launches coronavirus vaccine study in downtown Seattle
Mar 9, 2020, 12:42 PM
A sample of coronavirus is tested in a lab. (Getty Images)
(Getty Images)
At least nine separate companies are working to develop a coronavirus vaccine, including Kaiser Permanente Washington.
State continues to deal with ‘staggering’ lag in coronavirus testing
Kaiser’s Seattle facility will be conducting a vaccine trial study over the next year, looking to enroll 45 health adult patients as volunteers.
Adults between the ages of 18 and 55 are eligible, although those with “certain health conditions” may not be included. Conditions that affect the immune system are considered particularly problematic for potential participants.
The vaccine study will not infect patients with the virus itself. Rather, it will be “similar to investigational mRNA vaccines developed for the Zika virus and human metapneumovirus that have been tested in humans.”
Inslee weighs ‘mandatory measures’ as coronavirus outbreak continues
“The goal of the study is to learn about the safety of the vaccine and how the immune system responds to it,” Kaiser Washington said in a news release.
Participants will be asked to come in for 11 in-person study visits, and to participate in four phone visits over 14 months. They will receive $100 per visit, and up to $1,100 for coming in for all 11.
That includes one initial screening visit, two visits to receive the vaccination, and eight follow-up visits to monitor progress. Doses of the vaccination will be administered 28 days apart.
The in-person visits will take place at Kaiser Washington’s downtown Seattle research clinic near I-5; participants will be able to park for free in the building’s garage.
